Five actions to consider as you plan for an EU CGT submission
All cell and gene therapies will be required to align with the new European regulation on health technology assessment (HTA) by 2025 in order to gain market access in Europe. In this white paper, Evidera HTA experts discuss the effect of the regulation on companies with CGT products in the pipeline, five potential challenges and related opportunities or actions to consider for successful market access.
Complete the form to access the presentation.